Trevi's Haduvio meets Phase 2 CANAL primary endpoint; 52% placebo-adjusted cough reduction in IPF patients

Trevi Therapeutics, Inc.

Interim analysis (N=26) showed 52% placebo-adjusted reduction in daytime cough frequency (p<0.0001); 100% probability of success.
Company stops further recruitment into CANAL trial based on strong and consistent interim data.
Haduvio well tolerated; no new safety signals; one unrelated SAE reported.
Full CANAL trial data expected early Q3 2022, with approximately 40 total subjects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.